In collaboration with our academic partner TRICALS, Cytokinetics is conducting a Phase 3 trial to determine the safety and efficacy of their investigational drug reldesemtiv for the treatment of ALS.

Reldesemtiv

Reldesemtiv was developed by Cytokinetics in order to counteract the decline in muscle function. In a Phase 2 study, the drug was tested in people with ALS for a 12 week period. The current study is testing its effectiveness in the longer term and in a larger group of people.

All information on the study design, entry criteria and participating TRICALS centers can be found here at the TRICALS website.